Form 4: RVMD General Counsel Sells Shares for Tax Obligations
Insider Transaction Report
Revolution Medicines' General Counsel, Jeff Cislini, sold 2,688 shares of common stock at $76.8169 per share to cover tax withholding obligations.
Summary
- Jeff Cislini, General Counsel of Revolution Medicines, Inc. (RVMD), sold 2,688 shares of common stock.
- The transaction occurred on December 16, 2025, at a price of $76.8169 per share.
- This sale was executed under a Rule 10b5-1 plan adopted on May 31, 2023, specifically to satisfy tax withholding obligations upon the vesting of restricted stock units.
- Following this transaction, Cislini beneficially owns 47,884 shares, which includes 147 shares acquired via the Employee Stock Purchase Plan on November 30, 2025, and 38,769 restricted stock units.
Sentiment
Score: 5
Explanation: The filing reports a routine, non-discretionary sale of shares by an insider to cover tax obligations, which is a neutral event and does not indicate any particular positive or negative sentiment towards the company.
Positives
- The sale was pre-planned under a Rule 10b5-1 plan, indicating a non-discretionary transaction for tax purposes rather than a discretionary sale based on market outlook.
- The General Counsel still retains a significant beneficial ownership of 47,884 shares, including a substantial number of restricted stock units, aligning his interests with shareholders.
Future Outlook
No forward-looking statements or guidance are provided in this Form 4 filing.
Industry Context
This Form 4 filing details a routine insider transaction for tax withholding purposes, which is a common occurrence across all industries for executives receiving equity compensation. It does not provide specific insights into broader industry trends or competitive landscape.
Comparison to Industry Standards
- This is a standard Form 4 filing reporting an insider transaction for tax withholding. Such transactions are common across publicly traded companies when executives' restricted stock units vest, and they need to cover tax liabilities. There are no specific comparable companies, projects, or results to assess against global benchmarks in this type of filing.
Stakeholder Impact
- Shareholders: Minimal impact as it's a routine, pre-planned tax-related sale by an insider, not indicative of a change in confidence. The insider retains significant holdings.
- Employees: No direct impact mentioned.
- Customers: No direct impact mentioned.
- Suppliers: No direct impact mentioned.
- Creditors: No direct impact mentioned.
Key Dates
| Date | Description |
|---|---|
| 2023-05-31 | Rule 10b5-1 instruction letter adopted. |
| 2023-07-15 | Date after which tax withholding obligation upon RSU vesting applies. |
| 2025-11-30 | 147 shares acquired under the Issuer's Employee Stock Purchase Plan. |
| 2025-12-16 | Date of common stock transaction (sale for tax withholding). |
| 2025-12-18 | Signature date of the reporting person's attorney-in-fact. |
Keywords
Revolution Medicines, RVMD, Jeff Cislini, General Counsel, Insider Trading, Form 4, Stock Sale, Tax Withholding, Rule 10b5-1, Restricted Stock Units, Employee Stock Purchase Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.